Skip to content
Tuesday 8 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,815.73
-0.06%
DAX
25,909.83
-0.37%
CAC 40
8,285.35
-0.25%
STOXX 50
6,393.03
-0.17%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 30 October 2014 5:14 pm  |  Updated:  Friday 07 June 2019 2:40 pm

UK drug policy is decades out of date – it’s high time we faced up to the evidence

By: Charlotte Bowyer

Add as a preferred source on Google

After months of delays and political squabbles, the Home Office yesterday released its survey of international approaches to drug control. Examining the policies of 13 countries around the world, it failed to find “any obvious relationship between the toughness of a country’s enforcement against drug possession, and levels of drug use in that country”.

The report’s conclusions are at odds with 40 years of government policy, which centres upon the belief that harsh criminal penalties deter the (mis)use of drugs. It must have made for uncomfortable reading.

Though drug use has declined in recent years, there is little insight into why. In fact, there has never been a comprehensive study into the success or cost-effectiveness of our Misuse of Drugs Act, introduced in 1971 and barely altered since.

We urgently need an honest discussion of the law’s limitations. There’s plenty to get stuck into. Our “ABC” classification system is far too simplistic, failing to differentiate between drugs in terms of overall harm or addictiveness. Extremely harmful drugs like heroin are in the same class as ecstasy, which is statistically less dangerous to users than horse riding.

Drug prohibition directs resources from effective health measures to wasteful methods of enforcement – of 1.5m stop and searches on drug control grounds in 2011, only 7 per cent led to an arrest. Criminalising vulnerable users makes it harder for them to seek treatment and help, and unintended “displacement effects” occur when a clampdown on one substance leads to a surge in popularity in another.

This happened in 2009-10, when massive seizures of a key component in the manufacture of MDMA drove an explosion in the popularity of mephedrone, which is more dangerous but far cheaper, and was then more readily available.

Drug prohibition hands criminals an underground market worth over £200bn annually, and is responsible for deaths of tens of thousands of people in Latin America every year. The Home Office estimates that drug-related crime costs the UK over £13bn a year, with 45 per cent of acquisitive crime involving heroin and crack cocaine users trying to fund their habit.

Given the extreme economic and social costs of prohibition, our next step should be to look abroad, and to alternative ways of reducing drug-related harm. Portugal and the Czech Republic have adopted forms of decriminalisation, making it permissible to possess small amounts of all drugs for personal use.

In Portugal, the number of drug-related deaths and HIV cases among intravenous drug users has plummeted. Uruguay and the US states of Colorado and Washington have legalised the consumption and production of cannabis, placing it under varying degrees of state control. Early indications from Colorado have crime down 10 per cent, with a projected tax intake from recreational marijuana of $63m (£39.4m) in the first fiscal year.

The public is open to reform, and the evidence is clear that Britain needs it. But just a handful of MPs bothered to attend yesterday’s Parliamentary debate on the subject. Until politicians start taking the issue seriously, we’ll be stuck with laws that cause more harm than the drugs themselves.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Opinion

Categories

  • Opinion

Trending Articles

  • Hedge fund billionaire Chris Rokos joins UK wealth exodus 

  • Iceland boss Richard Walker vows to set up shop on Falkland Islands

  • Britain ‘taxing itself to death,’ Burnham warned

  • £74m for branded condoms? UK must stop spaffing cash on foreign aid

  • As it happened: FTSE 100 inche up as oil holds gains; Healey says UK paying ‘Truss penalty’

More from Morning Wire

  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

    Sport Business
    Evangelos Marinakis, owner of Nottingham Forest, in a dark jacket and white shirt, looking serious at a stadium.
  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

    FTSE 100 Live
    Donald Trump speaking at a podium, microphone visible, discussing the Strait of Hormuz
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children

    Business Wire
  • Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

    Business Wire
  • Whey and weight-loss drugs to eat into Applied Nutrition profit

    Retail
    Woman lifting dumbbells with a trainer in a busy gym, promoting fitness and health
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook